Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 16,833 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

NCT00194714
View directory record Official record
Conditions
HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
Interventions
HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 21, 2026, 9:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

NCT02912572
View directory record Official record
Conditions
Metastatic Endometrial Cancer
Interventions
Avelumab, Talazoparib, Axitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study

NCT05548881
View directory record Official record
Conditions
Cardiovascular Phenotype, Metabolic Phenotype, Hypertensive Disease, Psychological Phenotype, Audio
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English

NCT03726619
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
e-CHEC-uP, CHEC-uP
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

NCT03704467
View directory record Official record
Conditions
Ovarian Cancer
Interventions
M6620, Avelumab, Carboplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Greenbrae, California • Stamford, Connecticut • Saginaw, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 21, 2026, 9:50 PM EDT
Withdrawn Phase 3 Interventional

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

NCT01762592
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Iodine (124I) Girentuximab
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Burlington, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

sFlt-1:PlGF Ratio in Diagnosing Superimposed Preeclampsia

NCT03441711
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
University of Tennessee
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 21, 2026, 9:50 PM EDT
Not yet recruiting Not applicable Interventional

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

NCT07764744
View directory record Official record
Conditions
Ovarian Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Serous Tubal Intraepithelial Carcinoma, Early Detection of Ovarian Cancer
Interventions
Galleri Multi-Cancer Early Detection (MCED) Blood Test
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
35 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2039
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Kidney Transplant for HIV-Infected Patients in Renal Failure

NCT00009009
View directory record Official record
Conditions
Chronic Kidney Failure, HIV Infection
Interventions
immunosuppressive regimen designed to complement HAART
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

NCT01495663
View directory record Official record
Conditions
Cancer
Interventions
I-131-CLR1404
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Results available

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

NCT00796614
View directory record Official record
Conditions
Bladder, Neurogenic
Interventions
tamsulosin hydrochloride, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 16 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Relacorilant, Nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life

NCT01930981
View directory record Official record
Conditions
Hematologic Malignancies, Other Diagnoses, Comorbidities, and Complications
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 21, 2026, 9:50 PM EDT
Not listed Not applicable Interventional

Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)

NCT00114036
View directory record Official record
Conditions
Cardiovascular Surgical Procedures, Arthroplasty, Replacement, Hysterectomy
Interventions
Quality improvement strategies
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
Not listed
Timeline
2002 – 2005
U.S. locations
3
States / cities
Oakbrook Terrace, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer

NCT00005999
View directory record Official record
Conditions
Cervical Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 21, 2026, 9:50 PM EDT
Not listed Not applicable Interventional

Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer

NCT05227898
View directory record Official record
Conditions
Cancer
Interventions
Device: Attune™, Device: Cerena™
Device
Lead sponsor
Blue Note Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Patient Navigation During a Pandemic

NCT06208852
View directory record Official record
Conditions
Post-partum Depression
Interventions
Virtual Navigator Program
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

NCT00939952
View directory record Official record
Conditions
Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
Interventions
ertapenem
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Clifton Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 21, 2026, 9:50 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients

NCT05514847
View directory record Official record
Conditions
Preeclampsia, Pregnancy Related
Interventions
Aspirin 81Mg Ec Tab, Aspirin 162Mg Ec Tab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Withdrawn Not applicable Interventional

An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain

NCT04300907
View directory record Official record
Conditions
Postoperative Pain
Interventions
Provant Infinity Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Mesa, Arizona • Northridge, California • Eustis, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

NCT04792463
View directory record Official record
Conditions
Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Interventions
Not listed
Lead sponsor
Mohamed Abdel-Rahman
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional

Efficacy of rPMS for Improvement of Urinary Incontinence and Female Sexual Function

NCT03942484
View directory record Official record
Conditions
Urinary Incontinence
Interventions
rPMS device
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Louisville, Kentucky • Farmington Hills, Michigan • Hillsborough, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 21, 2026, 9:50 PM EDT